Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 124 The United Laboratories International Holdings Limited Annual Report 2025 30. SHARE CAPITAL (Continued) Notes: (i) During the year ended 31 December 2025, the Company repurchased its own ordinary shares for share award scheme through the Stock Exchange as follows: Month of repurchase No. of ordinary shares of HK$0.01 each Price per share Aggregate consideration paid Highest Lowest HK$ HK$ HK$’000 October 3,500,000 13.08 12.69 45,167,000 RMB’000 Shown in the consolidated financial statements as: At 31 December 2025 41,553 During the year ended 31 December 2024, the Company repurchased its own ordinary shares for share award scheme through the Stock Exchange as follows: Month of repurchase No. of ordinary shares of HK$0.01 each Price per share Aggregate consideration paid Highest Lowest HK$ HK$ HK$’000 October 3,700,000 11.20 10.04 40,382,000 RMB’000 Shown in the consolidated financial statements as: At 31 December 2024 36,557 (ii) At 31 December 2025, the Company had outstanding shares held for share award scheme of 224,020 (31 December 2024: 93,820). None of the Company’s subsidiaries purchased, sold or redeemed any of the Company’s listed securities during both years.